Tolerability and Overall Mortality in Patients With Non-idiopathic Pulmonary Fibrosis Progressive Fibrosing Interstitial Lung Disease Treated With Nintedanib: Real-world Evidence From a Single Specialist Centre

A39. MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES Pub Date : 2023-05-01 DOI:10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1522

P. Rivera Ortega, L. Stranks, K. Newman, T. Garfoot, H. Morris, K. Zakis, J. Swale, M. Greaves, S. Stanel, C. Avram, J. Blaikley, C. Hayton, C. Leonard

引用次数: 0

查看原文本刊更多论文

尼达尼布治疗的非特发性肺纤维化进行性纤维化间质性肺病患者的耐受性和总死亡率:来自单一专家中心的真实证据

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

A39. MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES

自引率

0.00%

发文量